Maverick Ventures

Health Tech

At ViVE, How Did VCs Respond to Criticism of Their Industry?

The financial outlook for the digital health sector is less than ideal, characterized by lower funding amounts, shrinking valuations, dwindling profitability and the collapse of Silicon Valley Bank. During a recent conference panel, four healthcare VCs discussed their reactions to this. They explained why the market has switched its focus from growth to value, as well gave advice to startups about what they need to know in this changing environment.

By Katie Adams
Health Tech

Which Digital Health Startups Are Most & Least Suited to Raise Capital in 2023?

Last year’s digital health investment trends have left some startups feeling uneasy about their ability to raise capital in the new funding environment. Venture capitalists think companies that have a demonstrable return on investment and serve multiple stakeholders will probably have the easiest time securing capital, while point solutions and startups in crowded markets will face a tougher environment.

By Katie Adams
sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

By PurpleLab